Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Income from Continuing Operations (2020 - 2026)

Rani Therapeutics Holdings' Income from Continuing Operations history spans 7 years, with the latest figure at 8015000.0 for Q1 2026.

  • On a quarterly basis, Income from Continuing Operations rose 37.08% to 8015000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 35651000.0, a 34.64% increase, with the full-year FY2025 number at 40374000.0, up 28.65% from a year prior.
  • Income from Continuing Operations came in at 8015000.0 for Q1 2026, up from 8498000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 7914000.0 in Q3 2025, with the low at 18664000.0 in Q2 2023.
  • Historically, Income from Continuing Operations has averaged 13895941.18 across 5 years, with a median of 14055000.0 in 2023.
  • Biggest five-year swings in Income from Continuing Operations: plummeted 191.08% in 2022 and later surged 45.95% in 2025.
  • Year by year, Income from Continuing Operations stood at 17372000.0 in 2022, then increased by 19.09% to 14055000.0 in 2023, then dropped by 11.86% to 15722000.0 in 2024, then skyrocketed by 45.95% to 8498000.0 in 2025, then rose by 5.68% to 8015000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for RANI at 8015000.0 in Q1 2026, 8498000.0 in Q4 2025, and 7914000.0 in Q3 2025.